Home Alzheimer’s Disease Nivolumab Demonstrates Durable Response in Refractory Biliary Tract Cancer

Nivolumab Demonstrates Durable Response in Refractory Biliary Tract Cancer

A phase II study published in JAMA Oncology found that nivolumab (Opdivo) was well tolerated and demonstrated moderate efficacy with durable response in patients with refractory biliary tract cancer (BTC). 

However, the researchers indicated that further studies are necessary to verify the findings and assess biomarkers for improved treatment selection for patients. 

“With the success of PD-1 blockade immunotherapy in melanoma, nivolumab has been extensively suited in the treatment of multiple tumor types, and emerging clinical data have demonstrated durable clinical activity and safety of nivolumab in various cancers,” the authors wrote. “However, only limited are reported on the role of immune checkpoint inhibitors in BTC owing to the rarity of the disease.” 

In this single-group, multicenter phase II study of nivolumab, researchers assessed 54 patients with…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Podcast Episode Interviewing Brain Cancer Fighter & Survivor : braincancer

Hi all, we have a podcast called Making Headway that is meant as a support for brain injury survivors. My co-host, Eryn, and I...

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...

Recent Comments